FINRA has also advised that as of June 20 Biofield will be uplisted off of the Pink Sheet Electronic OTC Markets and will trade on the OTC Bulletin Board under its new stock symbol BZEC.

Biofield will post on its website, www.biofield.com, the procedure, forms and other information needed by its transfer agent, American Stock Transfer and Trust Company, to exchange pre-split certificates for post-split certificates. For more information about the reverse stock split, see Biofield’s April 22 definitive information statement available at: http://www.sec.gov/Archives/edgar/data/1007018/000112178108000183/bio fielddef14c42208.htm. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

About Biofield Corp.:

Biofield Corp. is a development-stage medical technology company that has developed a device to assist in detecting breast cancer in a non-invasive procedure, the Biofield Diagnostic System (BDS). BDS employs single-use sensors designed by Biofield and a measurement device to detect and analyze changes associated with the development of epithelial cancers, such as breast cancer. For more information go to: www.biofield.com.

SAFE HARBOR STATEMENT: This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that our products may not achieve customer acceptance or perform as intended, that we may be unable to obtain necessary financing to continue operations and development, and other risks. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

The MacKay Group
David Bruce Hong, 852-2537-3230
dbh@theMacKayGroup.net
www.theMacKayGroup.net